Primary biliary cholangitis – Diagnostics – Overview of Information and Clinical Research

Understanding how primary biliary cholangitis (PBC) is diagnosed can help patients recognize when to seek medical care and what to expect during the diagnostic process. Early and accurate detection of this chronic liver condition is essential for starting treatment that may slow disease progression and prevent complications.

Introduction

Primary biliary cholangitis is a chronic condition that develops slowly, often without noticeable symptoms in its early stages. More than half of people diagnosed with PBC do not have any symptoms at the time of discovery. This means many cases are identified unexpectedly during routine blood tests ordered for completely different reasons, such as annual health screenings or investigations for other conditions.^[1]

If you experience persistent fatigue that doesn’t improve with rest, unexplained itchy skin that feels like it’s burning under the surface rather than on top, or dryness in your eyes and mouth, it’s advisable to see your doctor. These are common early symptoms that might prompt further investigation.^[2] Women between ages 40 and 60 are particularly at risk, as PBC affects females about ten times more often than males. If you have a family history of PBC or other autoimmune diseases, you should also be vigilant about getting regular check-ups.^[5]

People who already have other autoimmune conditions should be especially aware of the possibility of PBC. Conditions such as thyroid disease, Sjögren syndrome (which causes dry eyes and mouth), scleroderma, and Raynaud’s disease (a condition where fingers and toes become cold and change color) are more common in those who develop PBC. Women with PBC may also experience frequent urinary tract infections.^[5]

⚠️ Important

Many people with PBC feel completely well when first diagnosed, particularly in the early stages. The absence of symptoms does not mean the disease isn’t present. Regular blood tests as part of routine healthcare can catch PBC before symptoms develop, allowing for earlier treatment.

Diagnostic Methods

Blood Tests for Liver Function

The first step in diagnosing primary biliary cholangitis typically involves blood tests that check how well your liver is functioning. These tests measure the levels of certain proteins and enzymes that appear in higher amounts when bile ducts are damaged. Your doctor will look specifically at alkaline phosphatase (also called ALP), which is an enzyme that tends to be elevated in people with PBC.^[11] When the small tubes that carry bile through your liver become inflamed and damaged, this enzyme leaks into the bloodstream at higher levels than normal.

Liver function tests also check other markers such as aminotransferases, which are enzymes released when liver cells are damaged. Additionally, your doctor will measure bilirubin, which is a substance that builds up when bile cannot flow properly through the damaged ducts. High levels of bilirubin can cause the yellowing of skin and eyes known as jaundice.^[11]

Antibody Testing

One of the most reliable tests for diagnosing PBC is checking for specific antibodies in your blood. Antibodies are proteins made by your immune system, and in autoimmune diseases like PBC, the immune system mistakenly creates antibodies that attack the body’s own healthy tissues.^[7]

The key antibody test looks for antimitochondrial antibodies, usually shortened to AMAs or AMA-M2. These specific antibodies are found in more than 90 percent of people with PBC and are highly specific to this disease. This means if you test positive for these antibodies, it strongly suggests you have PBC, even if you don’t have symptoms yet.^[7] However, a small percentage of people with PBC do not have detectable AMAs, so other tests may be needed.

Doctors may also test for antinuclear antibodies (ANAs), which are often present in people with PBC. Specific patterns of ANAs can be observed through special laboratory techniques, and certain types like anti-sp100 and anti-gp210 antibodies can help confirm the diagnosis, especially when AMA tests are negative.^[7]

Imaging Tests

Once blood tests suggest the possibility of PBC, imaging tests help doctors get a clearer picture of what’s happening inside your liver and bile ducts. These tests also help rule out other conditions that might cause similar symptoms or blood test results.^[11]

Ultrasound is usually the first imaging test performed. This painless procedure uses sound waves to create pictures of your liver and surrounding organs. An ultrasound can show the size and shape of your liver and help identify any blockages or other problems with your bile ducts that aren’t caused by PBC.^[11]

A specialized type of ultrasound called FibroScan or transient elastography can measure the stiffness of your liver tissue. This test is particularly useful because it can detect scarring without needing to take a tissue sample. The stiffer your liver is, the more scarring has likely developed.^[11]

More advanced imaging may include magnetic resonance cholangiopancreatography, known as MRCP. This special type of MRI creates very detailed images of your liver and the network of bile ducts throughout it. This test is especially helpful in examining the structure of the ducts and ruling out blockages or other bile duct diseases.^[11]

Another specialized scan called magnetic resonance elastography (MRE) combines regular MRI with sound waves to create a detailed map showing areas of liver stiffness. This sophisticated test can detect scarring and help doctors assess how much damage has occurred.^[11]

Liver Biopsy

A liver biopsy involves removing a tiny sample of liver tissue so it can be examined under a microscope. In the past, this was commonly done to diagnose PBC, but nowadays it’s less often necessary. Most people can be diagnosed accurately using just blood tests and imaging.^[7]

However, a biopsy may still be recommended in certain situations. If your blood test and imaging results don’t clearly point to PBC, or if there’s a possibility you might have more than one liver condition at the same time, examining liver tissue directly can provide valuable information. The biopsy can confirm the diagnosis, show how advanced the disease is, and reveal whether other liver diseases are also present.^[11] During the procedure, a doctor safely removes a small tissue sample, typically using a needle inserted through the skin while the area is numbed.

⚠️ Important

A positive blood test for antimitochondrial antibodies (AMAs) combined with elevated alkaline phosphatase levels is usually enough to diagnose PBC without needing a liver biopsy. Most doctors can confirm the diagnosis based on these two findings alone, making the diagnostic process simpler and less invasive for most patients.

Cholesterol Testing

People with PBC often have unusually high cholesterol levels in their blood. More than half of those diagnosed with the condition experience extreme increases in blood fats, including total cholesterol. Testing cholesterol levels is a standard part of the diagnostic workup, as this finding supports the diagnosis and helps doctors understand the full impact of the disease on your body.^[11]

Diagnostics for Clinical Trial Qualification

Clinical trials studying new treatments for primary biliary cholangitis use standardized tests to determine who can participate. These enrollment criteria ensure that researchers can accurately measure how well a treatment works and that participants are likely to benefit safely from the experimental therapy being studied.

Liver Function Tests for Trial Entry

Clinical trials for PBC typically require specific blood test results showing that the liver is affected but not too severely damaged. Researchers measure alkaline phosphatase levels to confirm that bile duct damage is present and active. Trials often set a minimum level of ALP elevation as a requirement for enrollment, ensuring that participants have enough disease activity for researchers to see whether a treatment makes a difference.^[15]

Blood tests measuring bilirubin, albumin (a protein made by the liver), and transaminases (liver enzymes) help clinical trial teams assess how well your liver is functioning overall. If these levels show that cirrhosis has progressed to a very advanced stage, you may not be eligible for certain trials because the treatment might not be safe or effective at that point.^[15]

Antibody Confirmation

Most clinical trials require confirmation that participants have PBC through positive antibody testing. Testing positive for antimitochondrial antibodies is typically a standard entry requirement. Some trials may also accept patients who are AMA-negative but have been diagnosed through other means, such as liver biopsy results showing characteristic PBC features.^[7]

Treatment Response Assessment

If you’re already taking ursodeoxycholic acid (UDCA), which is the most common initial treatment for PBC, clinical trials will assess how well you’ve responded to it. They do this by measuring liver enzyme levels after you’ve been on the medication for a specific period, usually at least one year. People who don’t respond adequately to UDCA alone, shown by persistently elevated ALP or other liver markers, may be eligible for trials testing additional treatments.^[15]

Imaging Requirements

Clinical trials commonly require recent imaging tests such as ultrasound or FibroScan to document the current state of your liver. These images help researchers understand how much scarring has developed and rule out other complications like liver cancer. Some trials use magnetic resonance elastography to precisely measure liver stiffness before treatment begins, establishing a baseline for comparison as the study progresses.^[11]

Risk Stratification Tests

Researchers often use scoring systems that combine multiple blood test results to predict disease risk and progression. These scores help match patients to the most appropriate trials. For example, certain trials target people identified as having high-risk disease based on their biochemical response to standard treatment. Scoring models might incorporate alkaline phosphatase, bilirubin, albumin, and platelet counts to categorize patients into risk groups.^[15]

Some trials may also measure fibrosis (scarring) stage through elastography or biopsy. Understanding the stage of liver scarring helps researchers enroll people at similar disease stages so they can better evaluate whether new treatments slow progression or reverse damage.

Regular monitoring throughout the trial involves repeating these same blood tests and imaging studies at scheduled intervals. This ongoing testing allows researchers to track changes in liver function and determine whether the experimental treatment is having the desired effect. Most trials check liver function tests every three to six months and imaging tests annually or semi-annually depending on the study protocol.^[15]

Prognosis and Survival Rate

Prognosis

The progression of primary biliary cholangitis varies considerably from person to person. Some people experience very slow progression that takes decades, while others may see their condition worsen more quickly. The rate at which PBC progresses cannot be predicted with certainty at the time of diagnosis, but certain factors can help doctors estimate your outlook.^[6]

One of the most important factors affecting prognosis is how early you start treatment and how well you respond to it. People who begin taking ursodeoxycholic acid early in the course of PBC and show improvement in their liver blood tests tend to have much better outcomes. In fact, patients who respond well to UDCA can have a survival rate similar to people of the same age without PBC.^[15] This highlights why early diagnosis through routine blood testing can make such a significant difference.

Without treatment, PBC can eventually lead to cirrhosis, which is severe scarring throughout the liver. Once cirrhosis develops, complications such as fluid buildup in the abdomen, bleeding from enlarged blood vessels, and eventually liver failure may occur. However, current treatments can help slow down or even halt progression for many people, potentially preventing these complications entirely.^[2]

Approximately 20 to 30 percent of people with PBC do not respond completely to UDCA treatment alone, as shown by blood tests that remain abnormal after a year of therapy. These individuals typically have a higher risk of disease progression and may need additional treatments. Researchers use biochemical response after one year of UDCA to identify those who might benefit from adding other medications to their treatment plan.^[15]

Factors that indicate a less favorable prognosis include higher levels of bilirubin in the blood, low albumin levels, advanced age at diagnosis, and the presence of cirrhosis when first diagnosed. Regular monitoring through blood tests and imaging allows doctors to track these factors and adjust treatment approaches as needed.^[15] Even people with advanced PBC can sometimes live for many years with proper medical care and liver transplantation when necessary.

Survival rate

Many people with primary biliary cholangitis live for years or even decades after diagnosis, particularly when treatment begins early. Patients who achieve a good biochemical response to treatment—meaning their liver blood tests improve significantly—can expect survival rates comparable to the general population of similar age and gender.^[15]

However, survival depends heavily on the stage of disease at diagnosis and response to treatment. In untreated PBC or cases that don’t respond well to medication, the disease can progress to liver failure. Research shows that with appropriate treatment, the progression of PBC can be slowed substantially, extending life expectancy and maintaining quality of life for many years. The availability of liver transplantation as an option for those with advanced disease has also significantly improved survival outcomes for patients who develop severe complications.^[2]

#1 Clinical Trials Search in Europe

Primary biliary cholangitis – Diagnostics

Introduction